Thorac Cardiovasc Surg 2006; 54(4): 268-272
DOI: 10.1055/s-2005-873068
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Clinical Impact of Interstitial Pneumonia Following Surgery for Lung Cancer

Serum KL-6 is an Indicator?S. Takeda1 , H. Maeda1 , N. Sawabata1 , S. Kitada2 , M. Mori2 , S. Takashima3 , Y. Matsubara4
  • 1Department of Thoracic Surgery, National Hospital Organization, Toneyama National Hospital Toyonaka, City Osaka, Japan
  • 2Department of Pulmonary Medicine, National Hospital Organization, Toneyama National Hospital Toyonaka, City Osaka, Japan
  • 3Department of Radiology, National Hospital Organization, Toneyama National Hospital Toyonaka, City Osaka, Japan
  • 4Department of Anesthesiology, National Hospital Organization, Toneyama National Hospital Toyonaka, City Osaka, Japan
Further Information

Publication History

Received August 1, 2005

Publication Date:
02 June 2006 (online)

Abstract

Background: Operative morbidity in patients with lung cancer associated with perioperative interstitial pneumonia (IP) has emerged as a serious problem. Patients and Methods: We studied the clinical impact of perioperative related IP in 11 patients (IP group: 7 preoperative known, 4 acute onset) of 473 lung cancer patients who received a pulmonary resection. The IP group was compared to the remaining 462 patients (non-IP group). Demographic data, clinical presentation, and serum KL-6 levels were compared. Results: There were no differences in age, gender, type of surgery, and pulmonary function except for % DLco between the non-IP and IP groups. The IP group showed a higher in-hospital mortality (n = 2: 18.3 %) than that of the non-IP group (n = 3: 0.6 %) (p < 0.005). Seven patients with underlying IP with high KL-6 levels showed an uneventful recovery. Two patients with postoperative onset of acute IP had a fatal course associated with elevation of serum KL-6 levels. Conclusions: Postoperative development IP is a serious complication with high mortality, and serial measurement of KL-6 levels is useful to assess the activity of IP.

References

  • 1 Kutlu C A, Williams E A, Evans T W, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory syndrome after pulmonary resection.  Ann Thorac Surg. 2000;  69 376-380
  • 2 Wada H, Nakamura T, Nakamoto K, Maeda M, Watanabe Y. Thirty day operative mortality for thoracotomy in lung cancer.  J Thorac Cardiovasc Surg. 1998;  115 70-73
  • 3 Tanita T, Chida M, Hoshikawa Y. et al . Experience with fetal interstitial pneumonia after operation for lung cancer.  J Cardiovasc Surg. 2001;  42 125-129
  • 4 Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer.  Ann Thorac Surg. 2004;  78 999-1003
  • 5 Gross T J, Hunninghake G W. Idiopathic pulmonary fibrosis.  New Engl J Med. 2001;  345 517-525
  • 6 Nicholson A G, Colby T V, du Bois R M, Hansell D M, Wells A U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med. 2000;  162 2213-2217
  • 7 Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.  Am J Respir Crit Care Med. 2000;  161 5-8
  • 8 Matsushita H, Tanaka S, Saiki Y. et al . Lung cancer associated with usual interstitial pneumonia.  Pathol Int. 1995;  45 925-932
  • 9 Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exerbation in idiopathic pulmonary fibrosis: Analysis of clinical and pathologic findings in three cases.  Chest. 1993;  103 1808-1812
  • 10 Kumar P, Goldstraw P, Yamada K. et al . Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection.  J Thorac Cardiovasc Surg. 2003;  125 1321-1327
  • 11 Chiyo M, Sekine Y, Iwata T. et al . Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes.  J Thorac Cardiovasc Surg. 2003;  126 1141-1146
  • 12 Fujimoto T, Okazaki T, Matsukura T. et al . Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?.  Ann Thorac Surg. 2003;  76 1674-1679
  • 13 Martinod E, Azorin J F, Sadoun D. et al . Surgical resection of lung cancer in patients with underlying interstitial lung disease.  Ann Thorac Surg. 2002;  74 1004-1007
  • 14 Bouros D, Nicholson A C, Polychronopoulos V, du Bois R M. Acute interstitial pneumonia.  Eur Respir J. 2000;  15 412-418
  • 15 Goto K, Kodama T, Sekine I. et al . Serum levels of KL‐6 are useful biomarkers for severe radiation pneumonitis.  Lung Cancer. 2001;  34 141-148
  • 16 Nakahara K, Monden Y, Ohno K, Maeda H, Kawashima Y. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer.  Ann Thorac Surg. 1985;  39 260-265
  • 17 King T E, Costabel U, Cordier J F. et al . Idiopathic pulmonary diagnosis and treatment: International consensus statement.  Am J Respir Crit Care Med. 2000;  161 646-664
  • 18 Katzenstein A A, Myers J L. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification.  Am J Respir Crit Care Med. 1998;  157 1301-1315
  • 19 Kobayashi J, Kitamura S. KL‐6: A serum marker for interstitial pneumonia.  Chest. 1995;  108 311-315
  • 20 Sakuma T, Takahashi K, Ohya N, Usuda K, Handa M. Serum KL‐6, a novel mucin-like glycoprotein, as a indicator of intersitial pneumonitis following lobectomy.  Surg Today. 1999;  29 121-128
  • 21 Greene K E, King Jr T E, Kuroki Y. et al . Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.  Eur Respir J. 2002;  19 439-446
  • 22 Daniil Z D, Gilchrist F C, Nicholson A G. et al . A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med. 1999;  160 899-905
  • 23 Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis.  J Surg Oncol. 2002;  81 33-37
  • 24 Sato H, Callister M EJ, Mumby S. et al . KL‐6 levels are elevated in plasma from patients with acute respiratory distress syndrome.  Eur Respir J. 2004;  23 142-145
  • 25 Yaekashiwa M, Nakayama S, Ohnuma K. et al . Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study.  Am J Respir Crit Care Med. 1997;  156 1937-1944

MD, PhD Shin-ichi Takeda

Toneyama National Hospital

Toneyama 5 - 1 - 1

Toyonaka 560-8552

Japan

Phone: + 81668532001

Fax: + 816 68 50 17 50

Email: stakeda@toneyama.hosp.go.jp

    >